B2B Bladder & Kidney Cancers

Friday, May 25 - Workshops

• 13:00-17:30 Workshops
• 18:30-21:30 Trainee & Early Career Networking Dinner

Saturday, May 26 - Scientific Meeting

• 8:00-17:00 B2B Kidney and Urothelial Cancers Symposium

Join this annual meeting under the auspices of 

• Société Internationale d´Urologie (SIU)         
• Central European Urological Society (CEUS)
• Austrian-Polish Friends of Urology (FOU)
• Oncology, Laparoscopic-robotic, and Imaging Working Groups of the Austrian Urological Society ÖGU
• The Young Urology Working Group of the Austrian Urological Society ÖGU
• Comprehensive Cancer Center and the Department of Urology at the Medical University of Vienna

Overview

The 2nd B2B international congress will focus on key clinical topics in the management of kidney and bladder malignancies, including prognostic/predictive markers in care, proactive methods to mitigate predictable treatment-related side effects, optimal use of chemotherapeutic strategies, androgen-deprivation therapies, targeted therapies, radiopharmaceuticals and immonotherapies, as well as explore emerging data on various combinations and sequences of treatment strategies currently undergoing clinical trial evaluation.

The congress continues to evolve and expand its coverage of some of the fastest moving areas in the management of genitourinary malignancies. To that end, there will be an expanded focus on bladder cancer and renal cell carcinoma, given recent practice-changing developments that continue to alter the therapeutic landscape in these fields of care.

Key questions concerning the application of landmark clinical trial data on ermerging targeted and immunotherapeutic options, as well as the application of emerging biomarkers for these tumors, will be answered during expanded sessions on these topics.

Target Audience

This educational activity is directed toward medical, surgical and radiation oncologists involved in the treatment of patients with kidney and bladder malignancies. Urologists, fellows, nurses, physician assistants, pharacists, researchers, radiologists, nuclear medicine physicians, and other healthcare professionals interested in the treatment of kidney and bladder cancers may also participate.

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:

• Describe methods to stratify risk and tumor information that can provide the rationale for clinical decision making in the management of kidney and bladder cancers.
• Summarize recommendations that shape current strategies to care for patients with kidney and bladder cancers.
• Develop multidisciplinary strategies to optimize outcomes by proactive mitigation of known treatment-related side effects in caring for patients with kidney and bladder cancers.
• Assess recent practice-changing clinical trial findings concerning novel compounds or strategies to manage kidney and bladder cancers.
• Apply emerging clinical concepts to support the management of kidney and bladder cancers in consideration of evolving treatment paradigms in the field.